| 标题 |
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal? |
| 网址 | |
| DOI | |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)